eISSN: 2345-6558

Free Access

Journal of Parathyroid Disease 2018;6(2):72-73 doi: 10.15171/jpd.2018.22
Magnesium and parathyroid hormone among end-stage renal disease patients

Commentary

Seyed Seifollah Beladi Mousavi, Fatemeh Hayati, Shokouh Shayanpour, Shahla Ahmadi Halili *

1 Chronic Renal Failure Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.


*Corresponding author: Shahla Ahmadi Halili,
Email: Ahmadihalili@gmail.com


Abstract
Implication for health policy/practice/research/medical educationHypermagnesemia is also not a prominent feature among patients with chronic kidney disease, in the absence of increased magnesium administration, however renal failure mostly at its final stages is most common cause of hypermagnesemia.

Notes
Implication for health policy/practice/research/medical educationHypermagnesemia is also not a prominent feature among patients with chronic kidney disease, in the absence of increased magnesium administration, however renal failure mostly at its final stages is most common cause of hypermagnesemia.

Comments
First name  
Last name  
Email address  
Comments  
Security code



Article
PDF


Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks

Cite by
Google Scholar

Google Scholar
Articles by Seyed Seifollah Beladi Mousavi
Articles by Fatemeh Hayati
Articles by Shokouh Shayanpour
Articles by Shahla Ahmadi Halili
Similar articles
Related articles

PubMed
Articles by Seyed Seifollah Beladi Mousavi
Articles by Fatemeh Hayati
Articles by Shokouh Shayanpour
Articles by Shahla Ahmadi Halili


Article Access Statistics
Viewed
PDF Downloaded
Comments

Share this article!
Creative Commons Attribution 4.0 License This work is licensed under a Creative Commons Attribution 4.0 License.
Copyright © 2016 The Author(s)
Published by Nickan Research Institute